Furthermore, the effect of JAK1/2 inhibitors on the cytokine storm in MPN and targeted drugs for VEGF/VEGFR, HGF/c-MET, and SDF-1/CXCR-4 are discussed. The gene discussed is KDR; the disease is myeloproliferative disorder.